PA8556301A1 - Compuestos pirimidina de anillo fusionado alquinilado - Google Patents
Compuestos pirimidina de anillo fusionado alquiniladoInfo
- Publication number
- PA8556301A1 PA8556301A1 PA20028556301A PA8556301A PA8556301A1 PA 8556301 A1 PA8556301 A1 PA 8556301A1 PA 20028556301 A PA20028556301 A PA 20028556301A PA 8556301 A PA8556301 A PA 8556301A PA 8556301 A1 PA8556301 A1 PA 8556301A1
- Authority
- PA
- Panama
- Prior art keywords
- rent
- hydrogen
- descriptive memory
- groups
- rented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Abstract
UN COMPUESTO SELECCIONADO DE AQUELLOS DE LA FORMULA (I): EN DONDE W1 REPRESENTA O, S, O -NR3 EN DONDE R3 REPRESENTA HIDROGENO, ALQUILO, OH O CN; W2 REPRESENTA UN GRUPO SELECCIONADO DE HIDROGENO, CF3, NH2, MONOALQUILAMINO, DIALQUILAMINO, ALQUILO, ALQUENILO, ALQUINILO, ARILO, ARILALQUILO, CICLOALQILALQUILO, HETEROCICLO, ESTOS GRUPOS SON OPTATIVAMENTE SUSTITUIDOS; o W1 Y W2 FORMAN UN GRUPO DE LA FORMULA -N=X4-W3- DEFINIDO EN LA MEMORIA DESCRIPTIVA, X1, X2 Y X3 REPRESENTAN N O C OPTATIVAMENTE SUSTITUIDOS, N ES DE 0 A 8, Z REPRESENTA -CR12R13, EN DONDE R12 Y R13 SON LO DEFINIDO EN LA MEMORIA DESCRIPTIVA, A REPRESENTA UN SISTEMA DE ANILLO, LOS GRUPOS R2 REPRESENTAN HIDROGENO O DIVERSOS GRUPOS QUIMICOS DEFINIDOS EN LA MEMORIA DESCRIPTIVA, Q ES DE 0 A 7; R1 REPRESENTA HIDROGENO, ALQUILO, ALQUENILO, ALQUINILO, O UN SISTEMA DE ANILLO, Y OPTATIVAMENTE, SUS ISOMEROS OPTICOS, N-OXIDOS Y LAS SALES DE ADICION DE ELLOS CON UN ACIDO O BASE FARMACEUTICAMENTE ACEPTABLE Y PRODUCTOS MEDICINALES QUE LOS CONTIENEN SON UTILES COMO INHIBIDORES ESPECIFICOS DE LA METALOPROTEASA DE LA MATRIZ TIPO 13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2001/011824 WO2003033477A1 (en) | 2001-10-12 | 2001-10-12 | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor |
PCT/EP2002/008475 WO2004007469A1 (en) | 2002-07-12 | 2002-07-12 | New alkynylated quinazolin compounds as mmp-13 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8556301A1 true PA8556301A1 (es) | 2003-09-05 |
Family
ID=26069227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20028556301A PA8556301A1 (es) | 2001-10-12 | 2002-10-11 | Compuestos pirimidina de anillo fusionado alquinilado |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050245548A1 (es) |
JP (1) | JP2005509626A (es) |
AR (1) | AR037100A1 (es) |
BR (1) | BR0213239A (es) |
CA (1) | CA2463159A1 (es) |
MX (1) | MXPA04003008A (es) |
PA (1) | PA8556301A1 (es) |
PE (1) | PE20030541A1 (es) |
SV (1) | SV2003001289A (es) |
UY (1) | UY27485A1 (es) |
WO (1) | WO2003033478A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
CA2491820A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
CA2489722A1 (en) * | 2002-07-17 | 2004-01-22 | William Howard Roark | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003253176A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
WO2004014921A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
CA2497656A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
WO2005019188A1 (ja) * | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
CN106146413B (zh) * | 2015-04-03 | 2019-01-18 | 中南大学 | 2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途 |
CN112107602B (zh) * | 2020-09-08 | 2021-10-15 | 中国科学院烟台海岸带研究所 | 一对含双氮生物碱对映体及其制备和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902796A (en) * | 1986-10-20 | 1990-02-20 | The Trustees Of Princeton University | 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines |
US4818819A (en) * | 1986-10-20 | 1989-04-04 | The Trustees Of Princeton University | Process for the preparation of fused pyridine compounds |
US5608082A (en) * | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
JPH10195063A (ja) * | 1996-10-21 | 1998-07-28 | Dai Ichi Seiyaku Co Ltd | エチニルチアゾール誘導体 |
BR9714222A (pt) * | 1996-12-17 | 2000-04-18 | Du Pont | Método para o controle de doenças de plantas |
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-10-11 WO PCT/EP2002/012194 patent/WO2003033478A1/en not_active Application Discontinuation
- 2002-10-11 JP JP2003536218A patent/JP2005509626A/ja not_active Abandoned
- 2002-10-11 SV SV2002001289A patent/SV2003001289A/es not_active Application Discontinuation
- 2002-10-11 PE PE2002001007A patent/PE20030541A1/es not_active Application Discontinuation
- 2002-10-11 CA CA002463159A patent/CA2463159A1/en not_active Abandoned
- 2002-10-11 PA PA20028556301A patent/PA8556301A1/es unknown
- 2002-10-11 MX MXPA04003008A patent/MXPA04003008A/es unknown
- 2002-10-11 UY UY27485A patent/UY27485A1/es not_active Application Discontinuation
- 2002-10-11 BR BR0213239-7A patent/BR0213239A/pt not_active IP Right Cessation
- 2002-10-11 AR ARP020103820A patent/AR037100A1/es not_active Application Discontinuation
-
2005
- 2005-06-09 US US11/148,880 patent/US20050245548A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UY27485A1 (es) | 2003-05-30 |
MXPA04003008A (es) | 2004-07-16 |
JP2005509626A (ja) | 2005-04-14 |
CA2463159A1 (en) | 2003-04-24 |
US20050245548A1 (en) | 2005-11-03 |
AR037100A1 (es) | 2004-10-20 |
SV2003001289A (es) | 2003-06-24 |
BR0213239A (pt) | 2004-09-28 |
PE20030541A1 (es) | 2003-08-13 |
WO2003033478A1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8556301A1 (es) | Compuestos pirimidina de anillo fusionado alquinilado | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
CO4920234A1 (es) | Derivados de acidos arilsulfonilaminomidroxamicos | |
AR049670A1 (es) | Un derivado de acido aminometil carboxilico, su uso en el tratamiento de alteraciones del snc y una composicion farmaceutica que lo contiene | |
PA8568501A1 (es) | Compuestos oxo-azabiciclicos | |
PA8539401A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
ES2189251T3 (es) | Procedimiento de preparacion de diarilpiridinas utiles como inhibidores de cox-2'. | |
PE27299A1 (es) | Piridinas sustituidas utiles como inhibidores selectivos de ciclooxigenasa 2 | |
UY27699A1 (es) | Inhibidores. | |
AR001787A1 (es) | Un compuesto oxazolidin sustituido particularmenteutil como inhibidor de calpaina y/o catepsina b e n el tratamiento de trastornos neurodegenerativos agudos o cronicos y composiciones farmacéuticas que incluyen dicho compuesto | |
SV2002000875A (es) | Compuestos triazolo como inhibidores de mmp | |
AR051392A1 (es) | Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos | |
DE60205769D1 (de) | Verfahren zur herstellung von amphetaminen aus phenylpropanolaminen | |
ES2150978T3 (es) | Mezclas de aminas aromaticas alquiladas en el nucleo y de fenotiazinas. | |
AR004984A1 (es) | Proceso para la preparacion de compuestos de 2-clorotiazol, compuestos utiles para dicho proceso, y procesos para la preparacion de dichos compuestos intermediarios | |
ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
DOP2002000443A (es) | Proceso para produccion de quinazolinas | |
ES2176036T3 (es) | Sintesis quimica de derivados de morfolina. | |
DE60115080D1 (de) | Verfahren zur herstellung von bis-benzazolyl verbindungen | |
FI873009A (fi) | Foerfarande foer framstaellning av (2-dimetylaminoetyl)-/2-/(2-tiometylfenyl)-(fenylmetyl)/amino-2-oxoetyl /karbamater eller -karbamider. | |
AR004015A1 (es) | Procedimiento para preparar compuestos de quinolina o sales farmaceuticamente aceptables de los mismos, y compuestos intermediarios | |
AR034260A1 (es) | Proceso catalitico para la preparacion de derivados de tiazol | |
CO5251442A1 (es) | Uso de compuestos de 4-amino-1-fenilbutano-2-ol sustituidos en forma de sus racematos, enantiomeros diastereomeros o bases o sales correspondientes con acidos fisiologicamente tolerables como reguladores para el sistema nociceptina/ orfanina fq ligan | |
ES2174582T3 (es) | Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |